Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically

Ashraf H. Ahmed, Richard D. Gordon, Norlela Sukor, Eduardo Pimenta, Michael Stowasser

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background: Measurement of quality of life (QOL) allows assessment of the impact of a disease or treatment from the patient's perspective, including need for social, emotional, or physical support.We are not aware of any publishedQOLassessment in patients with bilateral primary aldosteronism (BPA), before or after commencing medical treatment (MT) with spironolactone and/or amiloride. Methods: Using the internationally validated Medical Outcomes Study Short Form 36 General Health Survey (SF-36),QOLwas assessed in 21 patients with BPA at baseline (time of diagnosis), and at 3 and 6 months after commencing MT. QOL scores at baseline were compared with published normative values for the Australian population. The results of the current study were compared with those from our previous study showing reduced QOL in patients with unilateral primary aldosteronism (UPA) with normalization by 3 months after unilateral laparoscopic adrenalectomy. Results: Compared with the general population, patients with BPA showed significant reduction (P < 0.01) in four QOL domains-physical functioning, role limitations due to physical health problems, general health perceptions, and vitality. After 6 months (but not 3 months) of MT, statistically significant (P < 0.05) improvements were detected in all these domains of QOL. When compared with patients with UPA treated surgically, scores were significantly (P < 0.05) lower at 3 months for five domains (role limitations due to physical health, general health, role limitations due to emotional health, mental health, and vitality) but at 6 months for only one domain (role limitations due to emotional problems). Conclusion: Subnormal QOL scores were improved after 6 months of MT in 21 patients with BPA, but more slowly and to a lesser degree than surgical treatment had previously been shown to improve QOL scores in 22 patients with UPA.

Original languageEnglish
Pages (from-to)2904-2911
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume96
Issue number9
DOIs
Publication statusPublished - Sep 2011
Externally publishedYes

Fingerprint

Spironolactone
Hyperaldosteronism
Amiloride
Quality of Life
Health
Therapeutics
Medical problems
Adrenalectomy
Health Surveys
Population
Mental Health
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{38be41c0b4a14e12bb0c5f617b3a1905,
title = "Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically",
abstract = "Background: Measurement of quality of life (QOL) allows assessment of the impact of a disease or treatment from the patient's perspective, including need for social, emotional, or physical support.We are not aware of any publishedQOLassessment in patients with bilateral primary aldosteronism (BPA), before or after commencing medical treatment (MT) with spironolactone and/or amiloride. Methods: Using the internationally validated Medical Outcomes Study Short Form 36 General Health Survey (SF-36),QOLwas assessed in 21 patients with BPA at baseline (time of diagnosis), and at 3 and 6 months after commencing MT. QOL scores at baseline were compared with published normative values for the Australian population. The results of the current study were compared with those from our previous study showing reduced QOL in patients with unilateral primary aldosteronism (UPA) with normalization by 3 months after unilateral laparoscopic adrenalectomy. Results: Compared with the general population, patients with BPA showed significant reduction (P < 0.01) in four QOL domains-physical functioning, role limitations due to physical health problems, general health perceptions, and vitality. After 6 months (but not 3 months) of MT, statistically significant (P < 0.05) improvements were detected in all these domains of QOL. When compared with patients with UPA treated surgically, scores were significantly (P < 0.05) lower at 3 months for five domains (role limitations due to physical health, general health, role limitations due to emotional health, mental health, and vitality) but at 6 months for only one domain (role limitations due to emotional problems). Conclusion: Subnormal QOL scores were improved after 6 months of MT in 21 patients with BPA, but more slowly and to a lesser degree than surgical treatment had previously been shown to improve QOL scores in 22 patients with UPA.",
author = "Ahmed, {Ashraf H.} and Gordon, {Richard D.} and Norlela Sukor and Eduardo Pimenta and Michael Stowasser",
year = "2011",
month = "9",
doi = "10.1210/jc.2011-0138",
language = "English",
volume = "96",
pages = "2904--2911",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "9",

}

TY - JOUR

T1 - Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically

AU - Ahmed, Ashraf H.

AU - Gordon, Richard D.

AU - Sukor, Norlela

AU - Pimenta, Eduardo

AU - Stowasser, Michael

PY - 2011/9

Y1 - 2011/9

N2 - Background: Measurement of quality of life (QOL) allows assessment of the impact of a disease or treatment from the patient's perspective, including need for social, emotional, or physical support.We are not aware of any publishedQOLassessment in patients with bilateral primary aldosteronism (BPA), before or after commencing medical treatment (MT) with spironolactone and/or amiloride. Methods: Using the internationally validated Medical Outcomes Study Short Form 36 General Health Survey (SF-36),QOLwas assessed in 21 patients with BPA at baseline (time of diagnosis), and at 3 and 6 months after commencing MT. QOL scores at baseline were compared with published normative values for the Australian population. The results of the current study were compared with those from our previous study showing reduced QOL in patients with unilateral primary aldosteronism (UPA) with normalization by 3 months after unilateral laparoscopic adrenalectomy. Results: Compared with the general population, patients with BPA showed significant reduction (P < 0.01) in four QOL domains-physical functioning, role limitations due to physical health problems, general health perceptions, and vitality. After 6 months (but not 3 months) of MT, statistically significant (P < 0.05) improvements were detected in all these domains of QOL. When compared with patients with UPA treated surgically, scores were significantly (P < 0.05) lower at 3 months for five domains (role limitations due to physical health, general health, role limitations due to emotional health, mental health, and vitality) but at 6 months for only one domain (role limitations due to emotional problems). Conclusion: Subnormal QOL scores were improved after 6 months of MT in 21 patients with BPA, but more slowly and to a lesser degree than surgical treatment had previously been shown to improve QOL scores in 22 patients with UPA.

AB - Background: Measurement of quality of life (QOL) allows assessment of the impact of a disease or treatment from the patient's perspective, including need for social, emotional, or physical support.We are not aware of any publishedQOLassessment in patients with bilateral primary aldosteronism (BPA), before or after commencing medical treatment (MT) with spironolactone and/or amiloride. Methods: Using the internationally validated Medical Outcomes Study Short Form 36 General Health Survey (SF-36),QOLwas assessed in 21 patients with BPA at baseline (time of diagnosis), and at 3 and 6 months after commencing MT. QOL scores at baseline were compared with published normative values for the Australian population. The results of the current study were compared with those from our previous study showing reduced QOL in patients with unilateral primary aldosteronism (UPA) with normalization by 3 months after unilateral laparoscopic adrenalectomy. Results: Compared with the general population, patients with BPA showed significant reduction (P < 0.01) in four QOL domains-physical functioning, role limitations due to physical health problems, general health perceptions, and vitality. After 6 months (but not 3 months) of MT, statistically significant (P < 0.05) improvements were detected in all these domains of QOL. When compared with patients with UPA treated surgically, scores were significantly (P < 0.05) lower at 3 months for five domains (role limitations due to physical health, general health, role limitations due to emotional health, mental health, and vitality) but at 6 months for only one domain (role limitations due to emotional problems). Conclusion: Subnormal QOL scores were improved after 6 months of MT in 21 patients with BPA, but more slowly and to a lesser degree than surgical treatment had previously been shown to improve QOL scores in 22 patients with UPA.

UR - http://www.scopus.com/inward/record.url?scp=80052525381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052525381&partnerID=8YFLogxK

U2 - 10.1210/jc.2011-0138

DO - 10.1210/jc.2011-0138

M3 - Article

VL - 96

SP - 2904

EP - 2911

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 9

ER -